Samuel Isaly just cannot get enough of Ascendis Pharma A/S (NASDAQ:ASND). According to an amended filing with the Securities and Exchange Commission, Isaly’s OrbiMed Advisors has recently acquired 371,514 shares of Ascendis, taking its tally to 3.67 million shares or 14.6% of the company’s outstanding stock. The fund has been actively buying Ascendis shares this quarter, having held only 222,223 shares at the end of March.
Based in Denmark, Ascendis Pharma A/S (NASDAQ:ASND) is a clinical stage biotech company that develops a number of prodrug therapies to address such deficiencies as growth hormone deficiency, pulmonary arterial hypertension and others. So far this year, the stock has been mostly in the red, falling by 26% to yesterday’s closing price of $13.27 per share. The company’s poor first quarter performance only made matters worse and put more pressure on the stock. Ascendis registered a loss of €0.82 ($0.92) per share and revenues of €1.3 million ($1.46 million), down by 40% year-over-year.
Ascendis Pharma A/S (NASDAQ:ASND) is not a very popular stock among the funds tracked by Insider Monkey, with only 10 of them having reported a stake in the company at the end of the first quarter, down from 11 registered at the end of December. Of the most prominent investors, Peter Kolchinsky and RA Capital Management had a sizable position in Ascendis Pharma, which amounted to 2.16 million shares. Julian Baker and Felix Baker‘s Baker Bros. Advisors held a more modest stake: 505,521 shares, unchanged over the course of the first quarter.
You can access the original SEC filing by clicking here.
Ownership Summary Table
|Name||Sole Voting Power||Shared Voting Power||Sole Dispositive Power||Shared Dispositive Power||Aggregate Amount Owned Power||Percent of Class|
|OrbiMed Capital GP V||0||3,671,976||0||3,671,976||3,671,976||14.6%|
|Samuel D. Isaly||0||3,671,976||0||3,671,976||3,671,976||14.6%|
Page 1 of 12 – SEC Filing
ASCENDIS PHARMA A/S
Telephone: (212) 739-6400
June 28, 2016